Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03611881 · ClinicalTrials.gov registry record · Phase 4

Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)

A Phase 4 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 4
Development phase
642
Enrollment target

NCT03611881: Completed Phase 4 study, sponsored by Massachusetts General Hospital.

NCT03611881 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 642 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (24% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03611881, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 4
Development phase
642 participants
Enrollment target

Study Summary

This randomized controlled trial seeks to evaluate the effectiveness of alternative strategies to integrate smoking cessation interventions into the delivery of low-dose CT (LDCT) lung cancer screening. Using a factorial design, current smokers who enroll will be randomly assigned to receive these interventions: (1) smoking cessation counseling support by telephone or videoconferencing (short duration vs. long duration); (2) nicotine patch treatment (NRT) (short vs.long duration); (3) counselor-facilitated referral (vs. no referral) to an online resource to connect smokers to a community-based social service resources.

Primary Outcome

Number of participants that self-reported no cigarette smoking in the past 7 days

Interventions

  • BEHAVIORAL Counseling
  • DRUG Nicotine patch
  • BEHAVIORAL Community Resource

Trial Details

FieldValue
Enrollment Target 642 participants
Start Date 2019-04-01
Est. Completion 2024-01-31
Phase Phase 4
Massachusetts General Hospital

2,032 total trials

What the finished NCT03611881 record still lists

NCT03611881 is an interventional study that assigns participants to a tested intervention. The registered 642 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (24% higher).

The record links to 0 conditions, and to 3 interventions - of which Counseling is the first listed.

NCT03611881 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03611881 about?

NCT03611881 is a clinical study titled "Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)". This randomized controlled trial seeks to evaluate the effectiveness of alternative strategies to integrate smoking cessation interventions into the delivery of low-dose CT (LDCT) lung cancer screening. Using a factorial design, current smokers who enroll will be randomly assigned to receive these i...

What is the current status of trial NCT03611881?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 642 participants. The study started on 2019-04-01. Estimated completion is 2024-01-31.

What interventions are being tested in trial NCT03611881?

The interventions under investigation include: Counseling (BEHAVIORAL), Nicotine patch (DRUG), Community Resource (BEHAVIORAL).

Who is sponsoring clinical trial NCT03611881?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03611881's enrollment target sits among peer trials

642 126th of 2000 higher than 1,875 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05204888 · 642 participants · NA

    myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

  • NCT06319820 · 641 participants · Phase 3

    A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  • NCT06625060 · 641 participants · Phase 2

    A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  • NCT05146297 · 644 participants · NA

    Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03611881, the US trial registry maintained by the National Library of Medicine. NCT03611881 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.